Fort Walton Rehabilitation Center, Llc | |
1 Lbj Sr Drive, Fort Walton Beach, Florida 32547 | |
(850) 863-2066 | |
Name | Fort Walton Rehabilitation Center, Llc |
---|---|
Location | 1 Lbj Sr Drive, Fort Walton Beach, Florida |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 120 |
Occupancy Rate | 81.25% |
Medicare ID (CCN) | 105295 |
Legal Business Name | Fort Walton Rehabilitation Center, Llc |
Ownership Type | For Profit - Limited Liability Company |
NPI Number | 1922099928 |
Organization Name | PHC-FT WALTON INC |
Address | 1 L B J Sr Dr, Ft Walton Beach, FL 32547 |
Phone Number | 850-863-2066 |
News Archive
Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.
Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.
Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, according to a Henry Ford Hospital study.
Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc.
› Verified 6 days ago
NPI Number | 1962788646 |
Organization Name | FORT WALTON REHABILITATION CENTER, LLC |
Address | 1 L B J Sr Dr, Fort Walton Beach, FL 32547 |
Phone Number | 850-863-2066 |
News Archive
Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.
Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.
Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, according to a Henry Ford Hospital study.
Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc.
› Verified 6 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.
Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.
Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, according to a Henry Ford Hospital study.
Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc.
› Verified 6 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 20.22 | 14.46 |
Percentage of long-stay residents who lose too much weight | 13.89 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 50.54 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.86 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.43 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 20.21 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0.96 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 3.22 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 94.86 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 18.58 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 72.76 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 2.77 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 37.56 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 29.39 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 5.58 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 86.85 | 95.98 |
Percentage of short-stay residents who made improvements in function | 81.7 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 62.11 | 82.93 |
News Archive
Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.
Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.
Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, according to a Henry Ford Hospital study.
Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc.
› Verified 6 days ago
Emerald Coast Center Location: 114 Third Street Se, Fort Walton Beach, Florida 32548 Phone: (850) 243-6134 | |
Fort Walton Rehabilitation Center, Llc Location: 1 Lbj Sr Drive, Fort Walton Beach, Florida 32547 Phone: (850) 863-2066 | |
Westwood Nursing And Rehabilitation Center Location: 1001 Mar-walt Drive, Fort Walton Beach, Florida 32547 Phone: (850) 863-5174 |